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Fig. 1. Claudin-1 localization in normal
human liver. Representative images of clau-
din-1 costained with markers specific for ap-
ical (CD10) or basolateral (cytokeratin 8)
membranes. Heterogeneous patterns of
claudin-1 at apical and basolateral mem-
branes were observed. Magnified volumetric
images (white box) prepared using Imaris
software demonstrate claudin-1 localization
around CD10, in keeping with a pericanalic-
ular tight junction distribution. Application of
low and high fluorescent intensity thresholds
discriminates apical tight junction-associated
(silver) and basolateral (yellow) pools of
claudin-1. Nuclei were stained with DAPI
(blue) and the scale bar represents 10 lm.
Heterogeneous Claudin-1 Expression in Human Liver
To the Editor:
We congratulate Mensa et al.1 on their report studying the
expression of hepatitis C virus (HCV) receptors claudin-1 and
occludin after liver transplantation and their influence on early vi-
ral kinetics. The authors provide a unique insight into the potential
role receptor expression levels play in modulating early phase viral
kinetics. They observed an association between HCV recurrence
and hepatocellular claudin-1 and occludin expression levels expres-
sion during the first week post liver transplant. The authors con-
firm the results of previous reports showing increased claudin-1
expression in HCV-infected liver.2,3 However, Mensa et al.
conclude that claudin-1 is solely located at the apical pole of
hepatocytes, in contrast to reports by Reynolds et al. and Zadori
et al.2,3 We agree that claudin-1 is predominantly expressed at the
apical membrane of hepatocytes in normal liver; however, a minor
pool of claudin-1 is observed at the basolateral membrane (Fig. 1).
Basolateral expressed claudin-1 is more easily discerned when the
liver section is co-stained with a marker for the hepatocellular
membrane such as cytokeratin 8 (Fig. 1B), enabling one to observe
heterogeneous patterns of localization across the liver parenchyma.
The discrepancies between these studies are most likely explained
by the imaging technique and analytical software employed. Spec-
tral imaging of liver sections enables the accurate quantification of
bound fluorescent antibody irrespective of signal intensity.
However, volumetric imaging of claudin-1 at areas of high (apical)
and low (basolateral) expression requires multiple threshold values
(Fig. 1). In contrast, Mensa et al. quantified volumetric images of
claudin-1 using a single threshold value, leading to a potential bias
in their protein quantification and an underrepresentation of
basolateral claudin-1. In conclusion, Mensa et al. have highlighted
a role for viral receptor expression in defining HCV kinetics
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posttransplant, warranting further investigation to study the role of
host pathways and inflammatory responses that regulate viral recep-
tor hepatocellular expression.
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Reply:
We appreciate the observations made by Harris et al. regarding
the differences in claudin-1 expression in human liver between the
report by Reynolds et al.1 and our work.2 The main objective of
our study was to assess the potential changes in tight junction pro-
teins claudin-1 and occludin following hepatitis C virus (HCV)
graft infection. We observed an increased expression of claudin-1
and occludin over time in HCV-infected patients. The increase in
claudin-1 was particularly significant in individuals with cholestatic
hepatitis. It is important to notice that when we applied very low
threshold values to create a surface for quantification, it was almost
impossible to discriminate basolateral claudin-1 staining from ei-
ther unspecific staining or tissue autofluorescence. More restrictive
thresholding guarantees the quantification of specific signal,
although it should be noted that this is at the expense of decreased
sensitivity. Thus, it is a possibility that we may have underesti-
mated claudin-1 expression in the basolateral membrane because
we quantified fluorescence intensity using a single threshold value.
The detection of minor pools of basolateral claudin-1 is an
interesting finding. Further studies are required to investigate the
role of nonjunctional claudin-1 in HCV entry and the physiopa-
thological consequences of increased levels of claudin-1 expression
in HCV disease progression.
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Clinical Relevance of Detectable Hepatitis C Virus RNA in the Context of Direct-Acting Antivirals
To the Editor:
Harrington et al. discuss the clinical relevance of detectable, but
not quantifiable, hepatitis C viral (HCV) RNA during treatment
with the two recently approved direct-acting antivirals (DAAs),
boceprevir and telaprevir.1 The clinical trials used to assess the effi-
cacy of these new DAAs were not designed to assess response-guided
therapy using the less than lower limit of quantification [LLOQ]
cutoff. However, a viremia below the LLOQ, but with detectable
amounts of virus, clearly indicates that peripheral clearance has not
occurred and, by implication, that replicating virus is still present in
the liver. The endpoint for the LLOQ for most clinical trials is 25
IU/mL (1.39 log10). The reduction in the sustained virological
response (SVR) rate between those patients that have a viremia less
than the LLOQ and those that have no detectable viremia clearly
indicates that lack of peripheral suppression is still a good surrogate
for persistence. No assay currently available detects HCV down to a
level of 0.001 IU/mL, as outlined in Figure 1 of Harrington et al.1
We have assessed the decreasing confidence interval (CI) associ-
ated with HCV reverse-transcriptase polymerase chain reaction (RT-
PCR) on a panel of characterized HCV genotype 1b samples (100,
37, 10, 3.7, 1, 0.37, and 0.04 IU/mL; AcroMetrix; Invitrogen, Carls-
bad, CA). The test platform was the Roche AmpliPrep and TaqMan
48 (Roche Molecular Diagnostics, Pleasanton, CA). Tests were repli-
cated between 13 and 25 times. A 100% hit rate was achieved for
the 100- and 37-IU/mL samples. A 95% CI was achieved at 9.914
(range, 5.737-26.578; n ¼ 13). Probit analysis yielded a 60% hit rate
at 2.624 IU/mL (95% CI: 1.782-4.241) and a 40% hit rate at 1.564
IU/mL (95% CI: 1.011-2.322). The assay did not yield detectable
RNA for the 0.37 and 0.04 IU/mL samples (n ¼ 25 and n ¼ 18,
respectively). We agree with Harrington et al.’s suggestion that vali-
dated cut-off LLOD points with appropriate CIs are applicable to
the provision of optimal care and maximizing of SVR rates. An
understanding of the decline in CIs surely makes the assessment of
end-of-treatment detectable (but below the LLOQ) results as false
positives too convenient an explanation.1 These transient viremias
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